344 related articles for article (PubMed ID: 25866814)
21. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents.
Tureyen K; Kapadia R; Bowen KK; Satriotomo I; Liang J; Feinstein DL; Vemuganti R
J Neurochem; 2007 Apr; 101(1):41-56. PubMed ID: 17394460
[TBL] [Abstract][Full Text] [Related]
22. Different sites of actions make different responses to thiazolidinediones between mouse and rat models of fatty liver.
Ebihara C; Aizawa-Abe M; Zhao M; Gumbilai V; Ebihara K
Sci Rep; 2022 Jan; 12(1):449. PubMed ID: 35013417
[TBL] [Abstract][Full Text] [Related]
23. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
24. Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function.
Borchert M; Schöndorf T; Lübben G; Forst T; Pfützner A
Diabetes Technol Ther; 2007 Oct; 9(5):410-20. PubMed ID: 17931049
[TBL] [Abstract][Full Text] [Related]
25. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists.
Antonelli A; Ferrari SM; Fallahi P; Frascerra S; Piaggi S; Gelmini S; Lupi C; Minuto M; Berti P; Benvenga S; Basolo F; Orlando C; Miccoli P
Endocr Relat Cancer; 2009 Dec; 16(4):1299-311. PubMed ID: 19755523
[TBL] [Abstract][Full Text] [Related]
26. Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery.
Rusinova R; Herold KF; Sanford RL; Greathouse DV; Hemmings HC; Andersen OS
J Gen Physiol; 2011 Aug; 138(2):249-70. PubMed ID: 21788612
[TBL] [Abstract][Full Text] [Related]
27. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1.
Copland JA; Marlow LA; Kurakata S; Fujiwara K; Wong AK; Kreinest PA; Williams SF; Haugen BR; Klopper JP; Smallridge RC
Oncogene; 2006 Apr; 25(16):2304-17. PubMed ID: 16331265
[TBL] [Abstract][Full Text] [Related]
28. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R.
Ferruzzi P; Ceni E; Tarocchi M; Grappone C; Milani S; Galli A; Fiorelli G; Serio M; Mannelli M
J Clin Endocrinol Metab; 2005 Mar; 90(3):1332-9. PubMed ID: 15585569
[TBL] [Abstract][Full Text] [Related]
29. [Recent trends in PPARgamma agonist development of thiazolidinediones and non-thiazolidinediones].
Tanaka T
Nihon Rinsho; 2010 Feb; 68(2):249-55. PubMed ID: 20158092
[TBL] [Abstract][Full Text] [Related]
30. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
Defronzo RA; Mehta RJ; Schnure JJ
Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
[TBL] [Abstract][Full Text] [Related]
31. X-ray crystal structure of rivoglitazone bound to PPARγ and PPAR subtype selectivity of TZDs.
Rajapaksha H; Bhatia H; Wegener K; Petrovsky N; Bruning JB
Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1981-1991. PubMed ID: 28499821
[TBL] [Abstract][Full Text] [Related]
32. Thiazolidinediones and inflammation.
Consoli A; Devangelio E
Lupus; 2005; 14(9):794-7. PubMed ID: 16218490
[TBL] [Abstract][Full Text] [Related]
33. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells.
Ohta K; Endo T; Haraguchi K; Hershman JM; Onaya T
J Clin Endocrinol Metab; 2001 May; 86(5):2170-7. PubMed ID: 11344222
[TBL] [Abstract][Full Text] [Related]
34. Peroxisome proliferator-activated receptor gamma ligand prevents the development of chronic pancreatitis through modulating NF-kappaB-dependent proinflammatory cytokine production and pancreatic stellate cell activation.
Hisada S; Shimizu K; Shiratori K; Kobayashi M
Rocz Akad Med Bialymst; 2005; 50():142-7. PubMed ID: 16358954
[TBL] [Abstract][Full Text] [Related]
35. Capacitative calcium entry contributes to the differential transactivation of the epidermal growth factor receptor in response to thiazolidinediones.
Dewar BJ; Gardner OS; Chen CS; Earp HS; Samet JM; Graves LM
Mol Pharmacol; 2007 Nov; 72(5):1146-56. PubMed ID: 17686966
[TBL] [Abstract][Full Text] [Related]
36. Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects.
Yoshizumi T; Ohta T; Ninomiya I; Terada I; Fushida S; Fujimura T; Nishimura G; Shimizu K; Yi S; Miwa K
Int J Oncol; 2004 Sep; 25(3):631-9. PubMed ID: 15289864
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo anti-melanoma effects of ciglitazone.
Botton T; Puissant A; Bahadoran P; Annicotte JS; Fajas L; Ortonne JP; Gozzerino G; Zamoum T; Tartare-Deckert S; Bertolotto C; Ballotti R; Rocchi S
J Invest Dermatol; 2009 May; 129(5):1208-18. PubMed ID: 19177142
[TBL] [Abstract][Full Text] [Related]
38. Possible Protective Effects of Thiazolidinediones Antidiabetic Drugs in Colorectal Cancer.
Bahrambeigi S; Badalzadeh R; Shafiei-Irannejad V; Alizadeh A
Crit Rev Oncog; 2019; 24(3):251-258. PubMed ID: 32422023
[TBL] [Abstract][Full Text] [Related]
39. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
40. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase.
Hazra S; Batra RK; Tai HH; Sharma S; Cui X; Dubinett SM
Mol Pharmacol; 2007 Jun; 71(6):1715-20. PubMed ID: 17412838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
